Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
55 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Show Display Options
RSS Create an RSS feed from your search for:
gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: Denosumab
2 Recruiting Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Condition: Breast Cancer
Intervention: Drug: Pegylated liposomal doxorubicin
3 Recruiting A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel + LCL161;   Drug: paclitaxel
4 Recruiting PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab;   Drug: Endocrine Therapy;   Drug: Paclitaxel
5 Recruiting Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate;   Drug: Placebo;   Procedure: Digital mammography;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis;   Procedure: fine-needle aspiration;   Other: pharmacogenomic studies;   Other: questionnaire administration
6 Recruiting DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Digoxin
7 Recruiting A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Conditions: Pre-treated Postmenopausal Patients With ER/PgR-negative/AR-positive or ER;   and/or PgR-positive/AR-positive Metastatic Breast Cancer
Intervention: Drug: DHEA (Dehydroepiandrosterone)
8 Recruiting PET Study of Breast Cancer Patients Using [68Ga]ABY-025
Condition: Breast Cancer
Intervention: Drug: [68Ga]ABY-025
9 Not yet recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
10 Recruiting CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Conditions: Metastatic Breast Adenocarcinoma;   Breast Cancer
Intervention: Drug: CR1447
11 Recruiting Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Eribulin
12 Not yet recruiting Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism
Condition: Breast Cancer
Intervention: Drug: Capecitabine
13 Recruiting A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Conditions: Head and Neck Neoplasms;   Lung Neoplasms;   Urinary Bladder Neoplasms;   Breast Neoplasms
Interventions: Drug: 5-Fluoro-2-Deoxycytidine (FdCyd);   Drug: Tetrahydrouridine (THU)
14 Recruiting A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Epirubicin+Cyclophosphamide;   Drug: liposomal-doxorubicin+Cyclophosphamide
15 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel
16 Recruiting LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Erismodegib;   Drug: Placebo
17 Recruiting Clinical Value of 89Zr-trastuzumab PET
Condition: Metastatic Breast Cancer
Intervention: Drug: 89Zr-trastuzumab injection
18 Not yet recruiting Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Condition: Breast Neoplasms
Interventions: Drug: Letrozole;   Drug: Afatinib
19 Unknown  Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride
20 Recruiting Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: veliparib;   Drug: cyclophosphamide;   Other: placebo;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years